Thursday, June 28, 2018 9:44:34 AM
Simulations Plus Names Shawn O’Connor as CEO
( The new guy has one helluva task ahead of him to improve on what Walt Woltosz has accomplished. )
LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that Shawn M. O’Connor will become its chief executive officer effective June 26, 2018.
Mr. O’Connor brings more than three decades of executive experience from multiple industries with companies ranging from start-ups to publicly traded companies and a proven track record for strategy definition, building strong organizations, optimizing revenue, profitability, and cash flow, and creating value for investors. He recently served as president, chief executive officer and a director of Entelos, a provider of unique quantitative systems pharmacology software and services to the pharmaceutical drug development market. Prior to Entelos, O’Connor served as chairman, president, and chief executive officer of Pharsight Corporation, a developer and marketer of software products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. In this role, he developed a software product strategy resulting in significant revenue, gross profit, and cash flow improvements, which resulted in a 20X increase in valuation. Mr. O’Connor earned a Bachelor of Science in business administration from the University of California at Berkeley and completed the Executive Education Program at Stanford University Graduate School of Business.
Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “The subject of the succession plan for Simulations Plus has been a topic of increasing importance. While my health is excellent and I continue to enjoy the work, it’s clear that we owe it to our shareholders, employees, and customers to have a solid succession plan, and, personally, the opportunity to retire while I can still do things that require significant physical activity makes sense. Accordingly, we are pleased to announce that Mr. Shawn O’Connor has been selected as the second CEO of Simulations Plus. I first became acquainted with Shawn in 2009 when we considered acquiring the assets of Entelos. Shawn has had a distinguished career in the pharmaceutical software industry with public companies serving as CEO of Entelos and Pharsight Corporation and as CFO of Diasonics, Inc., all of which operate in a similar product and market space as Simulations Plus. I am confident in his unique qualifications to lead the Company toward further growth and profitability. I will remain engaged with the company to assist Shawn during the transition and thereafter as an outside director.”
“Over the past 22 years, Walt’s vision and leadership have been the driving forces behind Simulations Plus becoming one of the most significant companies delivering innovative drug discovery and development software, clinical pharmacological consulting, and quantitative systems pharmacology models to drug developers,” stated Shawn O’Connor. “He has built a company committed to delivering for its customers, employees, and shareholders. I believe the opportunity that lies ahead for Simulations Plus is enormous, and I am honored and eager to be leading the company going forward. I have devoted the last 15+ years of my career to the development of in silico modeling for use in drug development and personalized medicine applications to impact patient outcomes positively and reduce health care costs, and I have never been as optimistic as now that the benefits of these efforts are being achieved at an accelerated pace and are poised for significant growth.”
https://finance.yahoo.com/news/simulations-plus-names-shawn-o-123000459.html
The only place where success comes before work is in the dictionary
Recent SLP News
- Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety • Business Wire • 07/11/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/08/2024 12:56:32 PM
- Apple Joins OpenAI Board, Logitech President Opts Out of Reelection, and More News • IH Market News • 07/03/2024 10:59:39 AM
- Simulations Plus Reports Third Quarter Fiscal 2024 Financial Results • Business Wire • 07/02/2024 08:06:00 PM
- Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit • Business Wire • 06/20/2024 12:30:00 PM
- Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date • Business Wire • 06/18/2024 12:30:00 PM
- QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus • Business Wire • 06/12/2024 12:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 12:00:28 PM
- Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum • Business Wire • 06/12/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:04:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:03:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:41:18 PM
- Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference • Business Wire • 05/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 09:00:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 08:56:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 08:53:03 PM
- Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software • Business Wire • 05/15/2024 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2024 08:24:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2024 08:21:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 08:42:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 08:39:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2024 08:20:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2024 08:20:26 PM
- U.S. FDA Renews DILIsym® Software Licenses for 7th Year • Business Wire • 04/04/2024 12:30:00 PM
- Exxon Mobil Forecasts Earnings Decline, Twilio Seeks Board Tenure Changes, and More News • IH Market News • 04/04/2024 11:30:20 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM